7.71

0.39% -0.03

After Hours: 7.56 -0.15 -1.95%

Seres Therapeutics Inc (MCRB)

Overview News Price History Option Chain Financials Discussions Forecast

Seres Therapeutics Inc stock is traded at $7.71, with a volume of 30,953. It is down -0.39% in the last 24 hours and up +16.29% over the past month. Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.

Previous Close:

$7.74

Open:

$7.65

24h Volume:

30,953

Relative Volume:

0.46

Market Cap:

$74.66M

Revenue:

$1.15M

Net Income/Loss:

$-46.90M

P/E Ratio:

-1.5364

EPS:

-5.0182

Net Cash Flow:

$-42.37M

1W Performance:

-1.03%

1M Performance:

+16.29%

6M Performance:

-50.42%

1Y Performance:

-35.05%

1-Day Range:

$7.54

$7.78

1-Week Range:

$7.48

$8.06

52-Week Range:

$5.31

$29.98

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name

Seres Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

617 945 9626

Address

200 SIDNEY STREET, CAMBRIDGE, MA

Employee

Twitter

@SeresTX

Next Earnings Date

2026-08-05

Latest SEC Filings

MCRB's Discussions on Twitter

Compare MCRB vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MCRB Seres Therapeutics Inc	7.71	76.41M	1.15M	-46.90M	-42.37M	-5.0182
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-08-25	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-24-24	Downgrade	JP Morgan	Neutral → Underweight
Jun-26-23	Resumed	Oppenheimer	Outperform
Apr-21-23	Initiated	JP Morgan	Neutral
Jul-23-21	Downgrade	Goldman	Neutral → Sell
May-18-21	Resumed	Goldman	Neutral
Mar-05-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Sep-18-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Aug-11-20	Upgrade	Jefferies	Hold → Buy
Apr-30-19	Initiated	Jefferies	Hold
Oct-22-18	Initiated	Chardan Capital Markets	Buy
Oct-13-17	Initiated	Oppenheimer	Outperform
Aug-04-17	Reiterated	H.C. Wainwright	Buy
Feb-01-17	Reiterated	FBR & Co.	Outperform
Aug-12-16	Reiterated	FBR Capital	Outperform
Aug-01-16	Downgrade	BofA/Merrill	Buy → Neutral
Aug-01-16	Reiterated	H.C. Wainwright	Buy
Jul-29-16	Resumed	H.C. Wainwright	Buy
Mar-30-16	Initiated	FBR Capital	Outperform
Mar-03-16	Initiated	Guggenheim	Buy
Jan-25-16	Initiated	H.C. Wainwright	Buy
Oct-22-15	Upgrade	BofA/Merrill	Neutral → Buy
Jul-22-15	Initiated	Canaccord Genuity	Buy
Jul-21-15	Initiated	Goldman	Neutral
Jul-21-15	Initiated	Leerink Partners	Outperform

View All

Seres Therapeutics Inc Stock (MCRB) Latest News

Jun 27, 2026

Price to sales forward of Seres Therapeutics, Inc. – NASDAQ:MCRB - TradingView

Jun 27, 2026

Jun 26, 2026

Price to earnings forward of Seres Therapeutics, Inc. – NASDAQ:MCRB - TradingView

Jun 26, 2026

Jun 25, 2026

Seres Therapeutics to Host Webcast on July 8, 2026, to - GlobeNewswire

Jun 25, 2026

Jun 24, 2026

This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm

Jun 24, 2026

Jun 23, 2026

This Insulet analyst begins coverage on a bullish note; here are top 5 initiations for Tuesday - MSN

Jun 23, 2026

H.C. Wainwright Initiates Seres Therapeutics(MCRB.US) With Buy Rating, Announces Target Price $12 - Moomoo

Jun 23, 2026

MCRB Initiates Coverage by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus

Jun 23, 2026

H.C. Wainwright initiates Seres Therapeutics stock coverage with buy rating - Investing.com

Jun 23, 2026

H.C. Wainwright initiates Seres Therapeutics stock coverage with buy rating By Investing.com - Investing.com Nigeria

Jun 23, 2026

HC Wainwright Initiates Seres Therapeutics at Buy With $12 Price Target - Moomoo

Jun 23, 2026

Jun 20, 2026

Total common shares outstanding of Seres Therapeutics Inc – DUS:1S90 - TradingView

Jun 20, 2026

Jun 18, 2026